Investor FAQs

Investor FAQs

Show All
Canada (Corporate Headquarter): 7210 Frederick-Banting, Suite 100, Montréal, Québec, Canada H4S 2A1
USA: 1 Broadway, 15th Floor , Cambridge, MA 02142, USA
Repare Therapeutics was incorporated under the Canada Business Corporations Act on September 6, 2016.
Repare Therapeutics was founded in 2016 by field-leading academics and Versant Ventures to systematically employ synthetic lethality insights and platforms and develop new precision oncology medicines.
Repare Therapeutics’s shares are traded on the Nasdaq Global Select Market under the symbol “RPTX.”
Repare Therapeutics’ initial public offering was on June 18, 2020.
Repare Therapeutics’ fiscal year ends on December 31.
Ernst & Young
900 Boulevard de Maisonneuve O bureau 2300,
Quebec H3A 0A8
Repare Therapeutics’s CUSIP number is 760273 102.
Shares of Repare Therapeutics’common stock can be purchased by contacting a securities broker of your choice.
Repare Therapeutics does not pay dividends at this time.
Repare Therapeutics’s transfer agent is Computershare Investor Services Inc. (Computershare). You can find more information about how to contact Computershare at:

Computershare Investor Services Inc.
1500 Robert-Bourassa Boulevard, 7th Floor
Montréal, Québec
Canada H3A 3S8

Phone: (800) 564-6253
If you have misplaced your share certificates, please contact Repare Therapeutics’ transfer agent, Computershare. There may be a fee involved for replacing lost share certificates.
If the shares are held in your name, you must contact Repare Therapeutics’s transfer agent, Computershare. If your shares are held in street name, you must contact your broker to update your address.
Filings may be accessed directly from the SEC’s website at by searching for:
i. Company name: Repare Therapeutics Inc.
ii. CIK Code: 0001808158
Please visit the “Investors” section of Repare Therapeutics’s corporate website and choose the “Email Alerts” link under “Info” to be added to the Repare Therapeutics distribution list.
Please email investor related questions to [email protected].
Media & IR Contact
Investor Contact

Robin Garner
Investor Relations
Contact Us

Media Contact

David Rosen
Argot Partners
[email protected]